Citalopram – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Citalopram (Celexa) is a Danish-developed SSRI from H. Lundbeck, approved in Europe in 1989 and in the US in 1998. It is sold as a 50/50 mix of two mirror-image molecules; only one of those mirror images, the (S) form, actually does the serotonin-blocking work. The other is mostly inert and may even slow the active half down. That insight led Lundbeck to repackage the active half on its own as escitalopram. Citalopram is among the most selective SSRIs for serotonin over other targets, which gives it a clean side-effect profile but does carry a dose-dependent risk of QT interval prolongation on the heart tracing, prompting the FDA to cap the daily dose at 40 mg in 2011. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Canonical SERT-selective reference probe; mature mechanism, real but narrow bench utility, superseded clinically by its own enantiomer

Honestly, citalopram earns a place in the library primarily as a pharmacological reference tool rather than as a research frontier. Approved by the FDA in 1998 and in Europe a decade earlier, it’s been around long enough that the mechanism literature is essentially complete: SERT inhibition, the CYP2C19/3A4/2D6 metabolic fingerprint, the QTc story, the downstream 5-HT receptor adaptations. Thats not a knock on the science; it’s just what a mature compound looks like.

What keeps it relevant is the selectivity profile. We’ve seen a lot of SSRIs, but citalopram’s greater-than-1000-fold selectivity for SERT over NET and DAT is genuinely exceptional in the class. If you’re running a mechanistic experiment and need to isolate serotonin transporter pharmacology without confounding adrenergic or dopaminergic effects, citalopram is your reference standard. That selectivity makes it a real probe tool in certain experimental designs, specifically anything probing pure serotonergic neurotransmission where norepinephrine leak would contaminate the read.

Here’s the thing about the racemate though: the (S)-enantiomer carries essentially all SERT activity, while the (R)-enantiomer is largely inactive but may attenuate (S)-enantiomer binding through an allosteric SERT interaction. This makes citalopram mildly interesting from a stereochemistry standpoint. You have a situation where one enantiomer acts as an allosteric modulator of the other’s primary target binding. Some groups have used this as a model system for studying allosteric SERT interactions — that’s about as novel as citalopram gets mechanistically in 2026, and it’s still a modest signal.

The QTc boxed warning issued by the FDA in 2011, which cut the maximum recommended dose from 60 to 40 mg, reflects a hERG channel interaction that any serious SSRI structure-activity program has to account for. For in vitro and cell-based work this is largely irrelevant, but worth knowing if you’re using it as a comparator in cardiac safety assays or ion channel screening.

We don’t think citalopram is worth prioritizing as a primary research target right now. The mechanism is fully characterized, the major clinical questions are answered, and escitalopram has replaced it in most contexts where you specifically want clean SERT activity. Where it remains genuinely useful: as a reference compound in SERT pharmacology work, in structure-activity relationship studies of the phthalane scaffold, and as a racemic SSRI comparator where you actually want the stereospecificity complexity in the assay design. The evidence base is massive and high quality — thats a real strength. But from a novelty and frontier standpoint, you’re not discovering new biology here. Use it as a tool; dont build a primary research program around it.

Novelty: 15
Mechanism promise: 20
In-category differentiation: 42
Evidence quality: 88
Translational signal: 78
Research bench value: 65

Rationale Citalopram’s exceptional SERT selectivity (>1000-fold over NET/DAT) preserves genuine probe value for serotonin transporter biology, but novelty and mechanism scores are floor-level for a fully characterized 1989 compound. The racemic/enantiomer story adds mild mechanistic texture, but the evidence and translational axes reward an approved drug with decades of RCT data, pulling the overall above the purely mature-workhorse range.

Selective serotonin reuptake inhibitor

A racemic phthalane SSRI; the most selective for SERT over NET in clinical use.

Abstract

Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 59729-33-8; molecular formula C20H21FN2O; molecular weight 324.39) is a bicyclic phthalane SSRI developed at H. Lundbeck in Denmark and approved in Europe in 1989 and by the FDA in 1998 under the trade name Celexa. The compound is sold as the racemate; the (S)-enantiomer (escitalopram) accounts for essentially all SERT inhibitory activity, while the (R)-enantiomer is largely inactive but may attenuate the (S)-enantiomer’s binding through allosteric SERT interaction. SERT affinity ((S)-enantiomer): Ki approximately 1 nM; selectivity over NET and DAT exceeds 1000-fold, making citalopram the most selective SSRI in clinical use. Plasma half-life is 33 to 37 hours; hepatic metabolism via CYP2C19, CYP3A4, and CYP2D6 produces minimally active metabolites. The compound is associated with dose-dependent QTc prolongation (FDA boxed warning issued 2011), with the maximum recommended dose reduced from 60 mg to 40 mg as a result. Used as the canonical selective SERT inhibitor in mechanism studies and as a reference compound in SSRI structure-activity work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-204Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.